3,4-dihydroxyphenylalaninechrome tautomerase
Biologicalexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2001 (NCT00022438)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TyrosinaseSTABILISER
TYR stabiliser
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3,4-dihydroxyphenylalaninechrome tautomerase
- dct protein, human
- dct protein, mouse
- dopachrome conversion factor
- dopachrome isomerase
- dopachrome oxidoreductase
- dopachrome tautomerase
- dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2), human
- mif-2 protein, human
- slaty protein, mouse
- trp2 protein, mouse
- trp-2 protein, tyrosinase-related
- tyrosinase-related protein-2
- tyrosinase-related protein-2
- tyrosinase-related protein 2, human
- tyrosinase-related protein-2, mouse
- tyrp2 protein, human
- tyrp2 protein, mouse
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00022438 | Phase 2 | Jun 1, 2001 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2001 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2001 |
2 organizations
Page 1 / 1